SCHEMBL8293243

SCHEMBL8293243

Cc1cc2c(cc1C)C(C)(C)CCN2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 5/20 0.48
RARB P10826 5/20 0.48
RXRA P19793 8/20 0.34
HNF4A P41235 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
PPARG P37231 2/20 0.32
RXRB P28702 4/20 0.32
RXRG P48443 3/20 0.32
RARG P13631 3/20 0.32
L3MBTL1 Q9Y468 1/20 0.30
MEN1 O00255 1/20 0.30
CYP26A1 O43174 1/20 0.30
ABCB11 O95342 1/20 0.30
ESR1 P03372 1/20 0.30
PGR P06401 1/20 0.30
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
CHRM1 P11229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8708359 0.86 RARA (0.44) RARARARBRXRAHNF4APTGS1
SCHEMBL12715251 0.83 RARA (0.43) RARARARBRXRAHNF4ARARG
SCHEMBL8700476 0.81 RARB (0.58) RARARARBRXRAHNF4APPARG
SCHEMBL8293242 0.78 RARA (0.48) RARARARBHNF4APTGS1PTGS2
SCHEMBL5023386 0.78 RARA (0.41) RARARARBHNF4ARARGMEN1
SCHEMBL17675356 0.73 RARB (0.44) RARARARBHNF4ARARGMEN1
SCHEMBL9143502 0.73 GABRA1 (0.38) RARARARBHNF4APTGS1PTGS2
SCHEMBL2978073 0.73 RARA (0.38) RARARARBHNF4ARARGL3MBTL1
SCHEMBL8699677 0.73 RARA (0.44) RARARARBRARGKMT2A
SCHEMBL12107981 0.73 HTR2C (0.36) RARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 US disclosed
EP-1692097-B1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2009-09-02 EP disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 US disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods HDAC5, HDAC1, HDAC2 RARA 1012/4885RARB 998/4885RXRA 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.